Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:
African American Hub News
 

Back to home » News & Views » Treatment News


 

January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007


emailrssprint

July 11, 2008

Therapeutic Vaccine Tanks in Study

In another setback to HIV immunization research, the ALVAC 1452 therapeutic vaccine led to higher viral loads and less time off antiretroviral (ARV) treatment in HIV-positive patients in a study published in the July 11 issue of AIDS and reported by AIDSmap.

Therapeutic vaccines have a long history in AIDS research. Experts have been using various types of vaccines to stimulate the immune systems of people living with HIV—notably those with undetectable viral loads while on ARV treatment—in hopes that the new, more robust immune responses will help control viral replication in the absence of therapy. This theory was supported with the positive results of an earlier vaccine candidate, ALVAC 1433.

With the newer vaccine, Brigitte Autran, MD, from the Institut National de la Santé et de la Recherche Médicale (INSERM) in Paris, and her colleagues enrolled 66 people taking ARV treatment with CD4 counts over 350. Twenty-two people were given four doses of ALVAC 1452 over a 20-week period, 22 people received three doses, and 22 were given placebo.

Four weeks after the last dose of the vaccine or placebo, 56 of the 66 patients chose to stop ARV treatment. They agreed to restart treatment if their CD4 count dropped either below 250 or more than 50 percent from when they started the study, or if their viral load climbed above 50,000.

Autran’s team found that patients who received the vaccine ended up with much higher viral loads than patients who received a placebo, and that those who got four doses of the vaccine had higher viral loads even than those who got just three doses. Moreover, people who got four doses of the vaccine were four times as likely as the placebo group to have to restart ARV treatment.

As with the failure of the Merck preventive vaccine, it appears that the vaccine-induced immune stimulation actually harmed people more than it helped them, and Autran’s team state that they are keen to discover the reasons why this occurred.

NEW! Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

  comments 1 - 1 (of 1 total)    

ArgentineanGuy, Buenos Aires, 2008-07-15 19:40:41
god.. news like this makes me feel so bad. When all this s... is going to end?

comments 1 - 1 (of 1 total)    


[Go to top]


Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Blogs by African-Americans
Antonia
Felipe
JC Jeanette
Pinnace
Kate
Ferguson

Read the blogs
Overheard in the Forums
"I'm HIV positive and diabetic (as well as have high cholesterol) and some of my meds specify taking them with 'high fat foods' which I have to do twice a day. I've eaten as healthy as possible, but when it comes to high fat foods, I am in a quandary...about what to eat sometimes..."

from Nutrition & HIV


Join the forums

Real Health Poll
Question: Do you know anyone who successfully quit smoking?
Yes
No

Smart + Strong Network
POZ Magazine
POZ Personals
POZ Mentor
POZ ASO Directory
AIDSmeds
Real Health Magazine
TuSalud Magazine
ComboCards
Rx Info Cards
Also visit POZ on...
Facebook

MySpace

YouTube

[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2009 Smart + Strong. All Rights Reserved. Terms of use and Your privacy